Why Are NRx Pharma's Shares Soaring Premarket?

NRx Pharmaceuticals NRXP has completed an analysis in the subgroup of Zyesami and placebo-treated patients previously treated with Gilead Science Inc's GILD remdesivir in the COVID-AIV trial representing approximately 70% of the study population.

  • The analysis indicates a substantial improvement after Zyesami (aviptadil) treatment in patients with critical COVID-19 and Respiratory Failure over existing therapies. 
  • Read Next: NRx Pharma Skyrockets After BriLife COVID-19 Vaccine Data Against Delta Variant.
  • The analysis identified a statistically significant 2.5 fold increased odds of being alive and free of respiratory failure at 60 days (the primary endpoint) and a statistically significant four-fold higher odds of being alive at day 60 among patients treated with aviptadil compared to those treated with placebo.
  • Baseline treatment with remdesivir was prespecified as a covariate in the protocol agreed to with the FDA. Before initiation of the trial, remdesivir did not show any independent survival or recovery advantage in the subgroup. 
  • The FDA recently declined Emergency Use Authorization and Breakthrough Therapy Designation for Zyesami and invited a new request based on new clinical evidence.
  • Price Action: NRXP shares are up 52% at $10.26 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 Coronaviruswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!